Bejelentkezés Regisztrálj ingyen

Adma Biologics Inc A részvények lebegnek

Mi az Adma Biologics Inc A részvények lebegnek?

A A részvények lebegnek az Adma Biologics Inc - 0.000 0.00%

Mi a A részvények lebegnek meghatározása?

Részvények úszó az a része, a vállalat részvényeinek, hogy a kezében az állami befektetők, szemben a bezárt raktáron.

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

A részvények lebegnek a Health Care szektor a NASDAQ-on cégekben a Adma Biologics Inc -hoz képest

Mit csinál Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

a részvények lebegnek -hoz hasonló cégek Adma Biologics Inc